Sato K, et al. - The goal with which this study was undertaken was to determine the efficacy and safety of capecitabine plus cisplatin (XP) as a first-line regimen for human epidermal growth factor receptor 2 (HER-2)-negative patients with advanced unresectable or recurrent gastric cancer (AGC). Findings suggested XP as first-line therapy was effective and well tolerated by patients with HER2-negative AGC.